What is Lifesci Capital’s Estimate for DFTX FY2026 Earnings?

Definium Therapeutics, Inc. (NASDAQ:DFTX) – Analysts at Lifesci Capital cut their FY2026 earnings per share (EPS) estimates for shares of Definium Therapeutics in a research note issued on Friday, June 5th. Lifesci Capital analyst F. Brisebois now expects that the company will post earnings of ($2.32) per share for the year, down from their prior forecast of ($2.31). The consensus estimate for Definium Therapeutics’ current full-year earnings is ($2.30) per share.

DFTX has been the subject of several other reports. HC Wainwright boosted their target price on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Piper Sandler reissued an “overweight” rating and issued a $48.00 target price (down from $49.00) on shares of Definium Therapeutics in a report on Friday, May 8th. Stifel Nicolaus set a $30.00 target price on Definium Therapeutics and gave the company a “buy” rating in a report on Thursday, April 16th. Oppenheimer reissued an “outperform” rating and issued a $40.00 target price on shares of Definium Therapeutics in a report on Thursday, April 23rd. Finally, Wolfe Research began coverage on Definium Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $25.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $37.92.

Definium Therapeutics Stock Down 2.3%

Shares of NASDAQ DFTX opened at $23.02 on Tuesday. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -9.24 and a beta of 2.37. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69. The business has a 50-day moving average of $21.92 and a two-hundred day moving average of $17.62. Definium Therapeutics has a 1 year low of $6.34 and a 1 year high of $26.25.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23).

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC increased its position in Definium Therapeutics by 2.4% in the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after acquiring an additional 1,165 shares during the period. Creative Planning increased its position in Definium Therapeutics by 2.6% in the 2nd quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after acquiring an additional 1,655 shares during the period. Rathbones Group PLC increased its position in Definium Therapeutics by 7.1% in the 3rd quarter. Rathbones Group PLC now owns 30,200 shares of the company’s stock valued at $356,000 after acquiring an additional 2,000 shares during the period. Bay Rivers Group increased its position in Definium Therapeutics by 14.3% in the 4th quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after acquiring an additional 2,000 shares during the period. Finally, Russell Investments Group Ltd. increased its position in Definium Therapeutics by 110.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the period. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.